NS-2330 · Triple Monoamine Reuptake Inhibitor · Protocol Guide
Tesofensine: The Honest Triple-Monoamine Guide
Tesofensine is not a peptide. The Phase IIb weight loss is real. The cardiovascular signal is real. The gray-market quality problem is real. This guide is direct about all three.
- FDA Status
- No FDA Approval, Phase IIb Halted
- Pharmacy
- Optimal Balance Pharmacy (503A licensed)
- Medical Service
- RxPepsDirect, physician-supervised + CV monitoring
- Access
- 28 U.S. States
Our promise: This guide includes the cardiovascular signal, the non-approval status, the psychiatric risk at higher doses, and the quality failures the gray market produces. If a claim is not backed by published clinical data, we say so.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 18, 2026.On this page
Section 01
What Tesofensine Actually Is
Tesofensine is a small-molecule triple monoamine reuptake inhibitor (SERT, NET, DAT) from the phenyltropane chemical family. It is closer to an antidepressant than to any peptide used in weight management.
Its origin is surprising. Originally developed by Danish firm NeuroSearch for Parkinson's disease and Alzheimer's disease, tesofensine failed both indications. Weight loss was a consistent side effect in overweight trial participants, which became the compound's new purpose. Phase IIb produced 9.2 percent weight loss at 0.5 mg over 24 weeks. Phase III was never completed. No FDA NDA was filed.
220 hrs
Half-life. Blood levels peak 5 to 8 hours and persist for days.
9.2%
Mean body weight loss at 0.5 mg over 24 weeks (TIPO-1, Astrup et al., 2008)
Phase IIb
Highest completed trial stage. No FDA NDA. No post-marketing safety surveillance.
"It's like cocaine, but no fun."
Section 02
Who It Is Actually For
| Profile | Goal | Fit |
|---|---|---|
| Treatment-resistant obesity with documented GLP-1 non-response | Aggressive weight loss after first-line therapy failure | Strong Fit |
| Plateau on GLP-1 receptor agonists (Tirzepatide / Semaglutide) | Adjunct or substitute when GLP-1 effect has plateaued | Physician Evaluation |
| Patients with controlled hypertension, no cardiac history | Modest weight loss with monitored cardiovascular signal | Monitored Use |
| Uncontrolled hypertension, recent cardiac event | N/A. Cardiovascular signal is a hard contraindication. | Contraindicated |
| Active psychiatric medication regimen | Triple-monoamine mechanism overlaps with SSRIs, SNRIs, TCAs. | Physician Decision Only |
Profile
Goal
Fit
Profile
Goal
Fit
Profile
Goal
Fit
Profile
Goal
Fit
Profile
Goal
Fit
Section 03
How It Works
Tesofensine blocks reuptake of three neurotransmitters simultaneously: dopamine, norepinephrine, and serotonin. The triple-reuptake mechanism increases synaptic concentrations of all three. The dopaminergic component reduces reward- driven food seeking. The noradrenergic component increases satiety and resting energy expenditure. The serotonergic component contributes to satiety.
Section 04
Realistic Expectations
Appetite Suppression Signal
Most patients notice meaningful appetite reduction within the first week. Blood pressure and heart rate should be monitored. Sleep disruption is common during the adaptation phase.
Measurable Weight Loss
Phase IIb data shows progressive weight loss accumulating from week 4 onward. Cardiovascular monitoring continues. Mood and anxiety changes may emerge in some patients.
Steady-State Loss
Body composition changes become visible. Trial mean was 9.2 percent loss at 24 weeks. Most patients respond well or do not respond at all by this point.
Phase IIb Endpoint
The longest documented protocol duration. Beyond 24 weeks is uncharted clinical territory and is not recommended without ongoing physician evaluation.
Section 05
Dosing Protocol
| Dose | Phase IIb Weight Loss | CV Signal | Notes |
|---|---|---|---|
| 0.25 mg per day | 4.5% at 24 weeks | Mild | Common starting dose. Some patients hold here. |
| 0.5 mg per day (RxPepsDirect standard) | 9.2% at 24 weeks | Moderate | The TIPO-1 primary dose. Strongest evidence base. |
| 1.0 mg per day | 10.6% at 24 weeks | Marked | Diminishing weight benefit, increased side effects. Rarely used clinically. |
Dose
Phase IIb Weight Loss
CV Signal
Notes
Dose
Phase IIb Weight Loss
CV Signal
Notes
Dose
Phase IIb Weight Loss
CV Signal
Notes
Tesofensine is an oral capsule, taken once daily in the morning with or without food. The 220-hour half-life means steady-state concentrations build over 2 to 4 weeks. There is no rescue dose option and no acute on-demand use case.
Side Effects and How to Manage Them
Tesofensine's side effect profile is the reason it did not advance to Phase III. The cardiovascular signal — blood pressure and heart rate elevation — is real and protocol-defining. The other side effects are common but manageable. This table and the cardiovascular monitoring section that follows it are the two most important sections in this guide.
| Side Effect | Frequency | When | Mitigation |
|---|---|---|---|
| Heart rate elevation / palpitations | Monitor — Phase IIb signal | Week 1 onward | Check resting pulse before each dose. If HR >100 bpm, contact provider. Dose reduction typically resolves. |
| Blood pressure increase | Monitor — Phase IIb signal | Week 1 onward | Daily BP check in weeks 1–4. If >140/90, contact provider immediately. Uncontrolled hypertension is a contraindication. |
| Dry mouth | Common (40–50%) | Ongoing | Active hydration throughout the day. Often improves after week 4 as the dopaminergic adaptation occurs. |
| Constipation | Common (25–35%) | Ongoing | Increase dietary fiber and water intake. Bulk-forming fiber supplement if persistent. |
| Insomnia or sleep disturbance | Common (20–30%) | First 2–4 weeks | Take dose in the morning. Avoid caffeine after noon. Usually resolves as the monoamine system adapts. |
| Mood changes, irritability (higher doses) | Uncommon at standard dose (10–15%) | If dose >0.5 mg | More common at 1 mg. If mood changes are significant, contact provider — dose reduction or discontinuation is the correct response. |
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Section 06
Cardiovascular Monitoring Is Not Optional
The cardiovascular signal in Phase IIb is the most important clinical fact about tesofensine. It did not produce events in the trial population, but it consistently elevated blood pressure and heart rate. Monitoring is the mechanism by which the protocol stays safe.
Blood Pressure + Resting HR
BP under 130/85, HR 60 to 90
Confirms candidacy for tesofensine. Out-of-range values are a contraindication.
BP + HR Recheck
Within 10 to 15 percent of baseline
The early phase is when CV signal emerges. Recheck values guide whether to continue, reduce, or stop.
Ongoing BP + HR
Stable
Tesofensine produces sustained elevation. Monthly check-ins ensure trends remain in safe range.
CMP + Lipids + Fasting Glucose
Provider-interpreted
Baseline metabolic panel for overall safety assessment. Repeated at 12 to 24 weeks.
Weekly Self-Monitoring Protocol
The cardiovascular monitoring schedule below is required, not optional. Log every reading with date and time so your provider has a trend to evaluate, not just a single value.
| Metric | Frequency | Tool | Signal to Report |
|---|---|---|---|
| Resting heart rate | Before each dose (daily) | Pulse oximeter or wearable | Resting HR >100 bpm before dosing — hold dose, contact provider same day |
| Blood pressure (systolic and diastolic) | Daily for weeks 1–4, then weekly | Home BP cuff | Systolic >140 or diastolic >90 — contact provider. Two readings >24h apart = urgent review |
| Weight | Weekly, same time and conditions | Scale | No weight change at week 8 — provider review to assess dose or protocol change |
| Mood and sleep quality (0–10) | Weekly | Phone note | Significant mood change, agitation, or worsening insomnia after week 4 — report |
Metric
Frequency
Tool
Signal to Report
Metric
Frequency
Tool
Signal to Report
Metric
Frequency
Tool
Signal to Report
Metric
Frequency
Tool
Signal to Report
Section 07
Ready to Take
1
Capsule per day
503A
Compounding pharmacy (Optimal Balance)
Monthly
Cardiovascular check-in
Section 08
Pricing
| Option | Medication Cost | Medical Cost | Notes |
|---|---|---|---|
| Gray Market (Research Vendor) | $30 to $80 per bottle, variable content | None (no prescription) | Independent testing has shown wide variation in actual content. Cardiovascular signal makes unverified product especially risky. |
| Other Online Clinics | $150 to $300 per month | Visit fees often bundled | Per-cycle pricing varies. Verify CV monitoring inclusion. |
| Optimal Balance Pharmacy + RxPepsDirect | $2.25 per capsule, paid to pharmacy | $39 visit fee, paid to RxPepsDirect | Cardiovascular monitoring built into the protocol. Labeled prescription. FedEx overnight shipping. |
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Section 09
Legal Access in 28 States
503A Licensed Pharmacy
Optimal Balance Pharmacy
Physician Prescription Required
Compounded medication, Rx only
Off-Label, Legal Practice
Not FDA-approved but legally prescribable
Not Controlled, Not Scheduled
No DEA classification despite dopaminergic mechanism
Tesofensine has never been FDA-approved. It is available through 503A patient-specific compounding under physician prescription. The compound is not scheduled by the DEA. Off-label prescribing of unapproved compounded substances is a legal practice provided the active ingredient appears on the FDA bulk drug substances list.
Section 10
Community Q&A
How does tesofensine compare to GLP-1s like tirzepatide?
Different mechanism, different side effect profile. GLP-1s work through gut-brain axis signaling. Tesofensine works through central monoamine modulation. GLP-1 trials produce 15 to 22 percent loss at the highest doses. Tesofensine Phase IIb produced 9.2 percent. GLP-1s carry GI side effects. Tesofensine carries cardiovascular and psychiatric considerations.
Can I stack tesofensine with an SSRI?
Generally no. Tesofensine inhibits serotonin reuptake. Combining with an SSRI risks serotonin syndrome. If you are on a psychiatric medication, your RxPepsDirect physician will evaluate whether tesofensine is appropriate.
Is the gray-market product the same?
Independent testing of research-chemical tesofensine has consistently shown wide variation in actual content, with some product containing under 50 percent of labeled dose. Given the narrow therapeutic window between weight-loss benefit and cardiovascular signal, this variation is dangerous. A 503A-compounded prescription is the safer route.
What happens if Optimal Balance is out of stock?
Your RxPepsDirect physician will be notified and you will be contacted before any delay impacts your protocol. You only pay the pharmacy when your prescription actually ships.
Section 11
The RxPepsDirect Model
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your tesofensine under a patient-specific prescription, USP <795> non-sterile compounding standards (oral capsules), and federal 503A oversight.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your history, screens for CV and psychiatric contraindications, designs your protocol, monitors blood pressure and heart rate, and writes the prescription. RxPepsDirect bills the $39 medical visit fee for this service.
Transparent Safety Communication
The guide flags the cardiovascular signal, the non-approval status, the SSRI interaction risk, and the gray-market quality problem. We do not hide limitations.
Legal Access in 28 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription.
References
- Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008. PMID: 18950853
- Schoedel KA, Meier D, Chakraborty B, et al. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010. PMID: 20485318
- Sjödin A, Gasteyger C, Nielsen AL, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010. PMID: 20531352
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
GLP-1 protocol guide
Microdose GLP-1: dosing math, evidence, and how to start safely in 2026
Microdosing semaglutide or tirzepatide means running them below the FDA-approved starter dose. The vial-duration math, the published evidence, and how to start with a provider.
Legal & regulatory
Are peptides legal in the United States in 2026?
Yes with a prescription through a 503A pharmacy. The full picture covers the 503A patient-specific exception, the research gray market, controlled substances, state variation, and WADA bans.
NNMT inhibitor (metabolic weight-loss)
5-Amino-1MQ protocol guide: the NNMT inhibitor mechanism, the mouse data, and the missing human trial
A small-molecule NNMT inhibitor that raises cellular NAD+ to push fat cells toward burning energy. All weight evidence is preclinical mouse and cell-culture work. Honest that no human trial exists.
Continue reading